JP4496127B2 - Herbal extract mixture and preventive or therapeutic agent for osteoporosis - Google Patents

Description

  The present invention relates to a herbal extract mixture obtained from eringi and five peels, and an agent for treating or preventing osteoporosis containing the same.

  Osteoporosis is caused by an imbalance between bone resorption and bone formation, and is caused by excessive progression of bone resorption over bone formation. When osteoporosis is suffered, the bone tissue lime is reduced, the dense bone becomes thin, and the bone marrow cavity becomes wide. And as the symptom progresses, the bone becomes weak, and it is easy to fracture even if it receives a small impact. The bone tissue is a dynamic tissue that is formed by osteoblasts and is repeatedly destroyed and resorbed by osteoclasts.

  In osteoporosis, rather than the symptoms themselves, life and activities are restricted for a long time by various fractures (especially femoral fractures and vertebral fractures) that are easily caused by bone weakness, and it is impossible to live a healthy life. is there. In addition, it is known that osteoporosis accounts for 15% of the causes of death in the elderly.

  Here, bone mass is affected by various factors such as genetic factors, nutrient intake, hormonal changes, exercise and lifestyle differences. The causes of osteoporosis are known to be old age, lack of exercise, low weight, smoking, low calcium diet, menopause, and ovariectomy. (Bone resorption level) is low and bone mass is large. In addition, bone mass is usually the highest at the age of 14-18 years, and decreases by about 1% a year after retirement. In particular, in the case of women, bone loss progresses continuously after 30 years of age, and bone loss rapidly advances due to hormonal changes when entering menopause.

  That is, when the menopause is entered, the concentration of estrogen rapidly decreases. At this time, a large amount of B-lymphocytes are produced by interleukin-7 (IL-7), and bone marrow (Bone marrow) accumulates B-cell precursors (pre-B cells), which increases the amount of IL-6 and increases the activity of osteoclasts. is there.

  As mentioned above, osteoporosis is an unavoidable symptom for elderly people, especially women after menopause, to some extent, and interest in osteoporosis and its therapeutic agents increases as the population ages in developed countries. It is coming. In addition, it is said that a global market of about $ 130 billion is formed for the treatment of bone diseases, and since further expansion is expected in the future, global research institutes and pharmaceutical companies are A large amount of investment has been made in the development of disease treatment agents, and the development of bone resorption inhibitors is being actively promoted.

  However, with regard to osteoporosis as described above, research has been conducted mainly in the past mainly on bone minerals, that is, calcium and phosphorus metabolism abnormalities. However, remarkable progress has been made in investigating the pathogenesis. I couldn't see it. Among these, substances currently used as osteoporosis therapeutic agents include bisphosphonate preparations (alendronate, etidronate), hormone preparations (raloxifene), vitamin D preparations, calcitonin preparations, calcium preparations, and the like.

  However, the bisphosphonate preparation has a poor absorption rate and a strict method of taking, and may induce esophagitis. Hormone preparations must be taken for a lifetime, and side effects such as breast cancer, uterine cancer, gallstones and thrombosis may occur when administered for a long time. In addition, vitamin D preparations are expensive, and reliable effects cannot be expected. Calcitonin preparations are also expensive and the administration method is difficult. Calcium preparations have few side effects but have the disadvantage that their effects are limited to prevention rather than treatment.

Osteoporosis as described above cannot be treated only by short-term administration of drugs, and long-term administration of drugs is essential. For this reason, even when a drug is administered for a long period of time, there is a need for a new substance having no side effects as described above and having excellent medicinal effects.
Therefore, an object of the present invention is to provide a substance having no side effects as in the prior art even when administered for a long time and having an excellent medicinal effect against osteoporosis.

  In order to solve the problems as described above, the present inventors have focused on eringi and pentagonal skin in various compounds and materials, and as a result of intensive research on these various physiological activities, Herbal extract mixture with five skin extracts is non-toxic, has the ability to proliferate osteoblasts, inhibit osteoclast proliferation, and prevent and treat osteoporosis without side effects As a result, the present invention has been found to be effective.

  That is, the present invention relates to an osteoblast proliferating activity and osteoclast comprising a water extract of eringi or an equivalent eringi extract, and a water extract of quince or an equivalent quince extract. A herbal extract extract (composition) having growth inhibitory activity is provided.

  Here, “Pleurotus eryngii” is a dead parasite belonging to the genus Oleander, which grows naturally in the subtropical prairie and is called Boletus of the steppes or King oyster mushroom in Europe. . According to the East Medical Treasure Book, eringi is non-toxic, sweet and fragrant. In order to improve the function of the gastrointestinal tract and promote the circulation of the air, this medicine is suitable when the limbs are numb and force is not applied, or when the waist and knees are numb.

  The ingredients of eringi have not yet been fully elucidated, but there are reports that they are alkaline foods that lower cholesterol levels and have anticancer effects. Rich in protein and vitamins, it is said to be effective for tonsils, mastitis, dextrinosis and various adult diseases. In particular, in Japan, it is attracting widespread attention as a natural health food that is alkaline and has a large anticancer effect.

  On the other hand, “Acanthopanacis Cortex” is a shrub plant belonging to the Araliaceae family and is distributed only in the Far East Asia in the Northern Hemisphere. In South Korea, it is an endangered wild conservation plant. There are five types of five skins: stamen five skins, general five skins and incense five skins. In Kampo, it is classified as an upper drug with no toxicity or side effects, and roots and skins are used as medicines. The leaf contains Chiisanoside and has a pharmacological function, and the root contains not only pentakaside glycosides but also dilingin (Sylrgin) and coumarin glycosides. There are five pentacytic glucosides, Acanthoside B and D, and water-soluble polysaccharides that enhance immunity.

  Gokahide is said to have a hard and bitter taste, warmness, hepatic function and nerves to remove wind and moisture, and to help raise the spirit. It has also been used in cases where the foot is incapacitated by making up for five labors (faults caused by frail weakness) and seven wounds (seven types of symptoms caused by frailty). Long-term use is said to be effective in improving qi, protecting the stomach, strengthening energy, concentrating on the mind, improving motivation, relieving fatigue and preventing aging, and is said to clean dirty blood in the body. Furthermore, it is said to cure various symptoms such as pain in the back and spine, male wilt, damp vagina and female genital palsy.

The herbal extract extract according to the present invention as described above has 0.5 to 2.5 parts by weight of the eringi extract as a solid content and 0.5 to 5. It is preferable to contain 0 part by weight.
The present invention also provides an osteoporosis therapeutic or prophylactic agent comprising the above-described herbal material extract mixture as an active ingredient, and a health food containing the above-described herbal material extract mixture.

  ADVANTAGE OF THE INVENTION According to this invention, even if it administers for a long period, there is no side effect like the past, and the crude drug material extract mixture which has the outstanding medicinal effect with respect to osteoporosis can be provided.

The present invention relates to a water extract of eringi or an eringi extract functionally equivalent to this (an eringi extract having a common main active ingredient), and a water extract of quinca peel or a quince functionally equivalent to this. A herbal extract having an osteoblast growth activity and an osteoclast growth inhibitory activity, and a therapeutic or preventive agent for osteoporosis using the same And health food.
Above all, the herbal medicine extract mixture includes 0.5 to 2.5 parts by weight of the eringi extract as a solid content and 0.5 to 5.0 parts by weight of the pentagonal extract as a solid content. Is preferred.

  In the herring material extract mixture of the present invention, the eringi extract and the quince extract are respectively extracted with water, alcohol or an organic solvent (ether, n-hexane, dichloromethane, chloroform, etc.). Is obtained. First, the extraction method of eringi and pentagon is described below.

  In order to obtain an eringi extract, eringi is put into an extraction container, and distilled water is added thereto, for example, and hot water extraction is performed at 100 ° C. for 4 hours. After repeating the above process three times, the resulting solution is cooled at room temperature and filtered through filter paper. Then, the extract obtained by filtration is concentrated under reduced pressure at 40 ° C. or lower using a vacuum rotary evaporator and freeze-dried to obtain a powdered (solid) eringi extract. The eringi extract obtained by concentration in this manner may be separated by bioassay-directed fractionation using butanol, ethyl acetate, ethanol or the like.

  In addition, in order to obtain a five peel extract, as in the case of the eringi extract, the five peel is placed in an extraction container and, for example, distilled water is added and hot water extraction is performed at 100 ° C. for 4 hours. After repeating the above process three times, the resulting solution is cooled at room temperature and filtered through filter paper. Then, the extract obtained by filtration is concentrated under reduced pressure at 40 ° C. or lower using a vacuum rotary evaporator to obtain a powdered (solid) pentagonal extract. The five peel extract obtained by concentrating in this way may be separated by activity tracking fractionation using ethanol or the like.

The crude drug material extract mixture according to the present invention can be obtained by mixing the eringi extract and the pentagonal extract obtained as described above in the above mixing ratio. The method of mixing the eringi extract and the pentagonal extract is not particularly limited, and may be mixed by a conventional method.
Moreover, the eringi and pentagonal skin used for the extraction step may be pulverized in advance, for example, in a powder form. Furthermore, first, eringi and five peels may be mixed to obtain a mixture, and the resulting mixture may be subjected to the extraction step to simultaneously produce an eringi extract and a five peels extract. Therefore, for example, after mixing powdered eringi and five peels, the herbal extract extract according to the present invention can be obtained by extraction from the mixture.

  The crude drug material extract mixture according to the present invention thus obtained has a cell growth effect of about 120 to 130% or more compared to the case where the eringi extract and the five-cattle extract are used alone, The activity of basic phosphatase, which is a labeled cell of blast, is increased by about 110 to 150%. Moreover, the crude drug material extract mixture according to the present invention can remarkably suppress the formation of osteoclasts, compared to the case where the eringi extract and the pentagonal extract are each used alone.

That is, the crude drug material extract mixture according to the present invention exhibits an excellent activity for basic phosphatase, which is a marker enzyme for osteoblasts, has an effect on osteoblast proliferation, and produces osteoclasts. Since it is significantly suppressed, it can be effectively used for the prevention and treatment of osteoporosis.
In addition, the herbal extract extract according to the present invention may further contain one or more active ingredients exhibiting the same or similar function as these in addition to the above-mentioned eringi extract and pentagonal extract.

  The herbal extract extract can be administered orally or parenterally during clinical administration, and can be used in the form of a general pharmaceutical preparation. That is, the crude drug material extract mixture according to the present invention can be administered in several dosage forms, oral and parenteral, at the time of actual clinical administration. What is necessary is just to prepare using diluents or excipient | fillers, such as an agent, a binder, a wetting agent, a disintegrating agent, and surfactant.

  Examples of solid preparations for oral administration include tablets, pills, powders, granules and capsules. Such a solid preparation can be prepared by mixing at least one or more excipients such as starch, calcium carbonate, sucrose, lactose and gelatin with the herbal extract extract. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Liquid preparations for oral administration include suspensions, solution-resistant agents, oils and syrups, but various excipients in addition to water and liquid paraffin, which are widely used simple diluents. For example, wetting agents, sweetening agents, fragrances and preservatives may also be applicable.

  Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, oils, lyophilizers, suppositories, and the like. Non-aqueous solvents and suspension solvents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl allate. As a suppository base, witepsol, macrogol, tween 61, cacao butter, lauric butter, glycerol and gelatin can be used.

  The range of dosage varies depending on the patient's weight, age, sex, health status, diet, administration time, method of administration, excretion rate and severity of the disease. The daily dose may be 150 to 450 mg / kg, preferably 300 to 400 mg / kg, for the herbal extract mixture. Moreover, administration 1-6 times a day is possible.

Here, as a result of oral administration of the crude drug material extract mixture according to the present invention to rats, a 50% lethal dose (LD ₅₀ ) by oral administration toxicity test is at least 1 g / kg or more, which is a safe substance It is judged that.

  The crude drug material extract mixture according to the present invention can be used alone for the prevention and treatment of osteoporosis, but is a method of using surgery, radiation therapy, hormone therapy, chemical therapy and biological response modifier. Can be used in combination with

  In addition, the herbal extract extract according to the present invention can be added to health foods (including beverages) ingested for the purpose of prevention and improvement of osteoporosis. When the crude drug material extract mixture according to the present invention is used as a food additive, the crude drug material extract mixture may be added as it is, and can be used together with other foods and food ingredients. Can be used as appropriate.

  The amount of the active ingredient of the health food according to the present invention (that is, the herbal extract extract according to the present invention) can be appropriately determined according to the purpose of use (prevention, health maintenance or therapeutic treatment). In general, during the production of food or beverage, the herbal extract extract according to the present invention is added as a solid content in an amount of 15% by weight or less, preferably 10% by weight or less, based on the raw material of the food or beverage. . The lower limit may be about 3% by weight. For example, in the case of green tea, it is preferable to drink 9 cups or more for one year or more. However, when ingested over a long period of time for the purpose of maintaining health and hygiene, or for the purpose of regulating health, the amount may be smaller, while there is no problem in terms of safety. The amount may be larger.

  The type of the health food according to the present invention (that is, the composition containing the crude drug material extract mixture according to the present invention as an active ingredient) including the crude drug material extract mixture according to the present invention is not particularly limited. Examples of health foods according to the present invention include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice creams, various soups, Examples include beverages, teas, drinks, alcoholic beverages and vitamin complexes, and all include health foods in the usual sense.

  The health drink of the health food according to the present invention may contain various flavoring agents or natural carbohydrates as additional components, as in a normal beverage. The above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and shoecloth, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of the sweetening agent include natural sweetening agents such as thaumatin and stevia extract, and synthetic sweetening agents such as saccharin and asphaltum. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g per 100 ml of the health drink according to the present invention (a composition containing the herbal extract extract according to the present invention as an active ingredient), preferably about 0.004. It may be 02 to 0.03 g.

  Furthermore, the health food according to the present invention (a composition comprising the herbal extract extract according to the present invention as an active ingredient) includes, as additives, various nutrients, vitamins, electrolytes, flavors, coloring agents, pectinic acid and Its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like can be included.

  In addition, the health food according to the present invention may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. Moreover, said additive can be used individually or in mixture, respectively. The ratio of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food according to the present invention.

  Hereinafter, the present invention will be described more specifically with reference to examples. However, these are only for clarifying the technical contents of the present invention, and the present invention is not limited to these examples.

Example: Production of Herbal Extract Extract Mixture
1. Manufacture of eringi extract 100 g of eringi was put in a 3 L extraction container, 1 L of distilled water was added, and hot water extraction was performed at 100 ° C. for 4 hours. After repeating the above process (a process of adding 1 L of distilled water and extracting with hot water at 100 ° C. for 4 hours) three times, the resulting solution (extract) was cooled at room temperature and filtered through a filter paper. The extract (filtrate) obtained by filtration was concentrated under reduced pressure at 40 ° C. or lower using a vacuum rotary evaporator and freeze-dried to obtain a powdered eringi extract (yield: 42%, freeze-dried). Solid content yield obtained by measuring post-solid content).

2. Manufacture of the five peels extract 100 g of five peels was put into a 3 L extraction container, 1 L of distilled water was added, and hot water extraction was carried out at 100 degreeC for 4 hours. After repeating the above process three times, the resulting solution was cooled at room temperature and filtered through filter paper. The extract obtained by filtration was concentrated under reduced pressure at 40 ° C. or lower using a vacuum rotary evaporator, and lyophilized to obtain a powdered five peel extract (solid content yield: 5.8%). ).

3. Preparation example of crude drug material extract mixture 0.5 to 2.5 parts by weight of eringi extract obtained in 1 above and 0.5 to 5.0 parts by weight of five peel extract obtained in 2 above are mixed Thus, a crude drug material extract mixture was produced.
The crude drug material extract mixture was diluted in a culture solution and used for the following experiment. That is, in the following experiment, each crude drug extract was diluted with the culture solution to the concentration shown in the table, and the experiment was conducted.

<< Experimental Example 1: Proliferation efficacy analysis of osteoblasts by the herbal extract of the present invention >>
In order to investigate the influence of the herbal extract mixture according to the present invention on the proliferation and cell activity of osteoblasts, the following experiment was conducted.

1. Proliferation and cell activity analysis of osteoblasts In order to evaluate the effect of the herbal extract mixture according to the present invention on the proliferation of osteoblasts, MG-63 and HOS cells, which are cell lines derived from human osteosarcoma The strain was purchased from ATCC (American Type Culture Collection, Rockville, USA) and used after being cultured in DMEM (Dulbecco's modified Eagle's medium) medium containing 10% FBS (fetal bovine serum).

MG-63 osteoblasts cultured above to indirectly assess whether the herbal extract mixture according to the present invention is toxic and to examine the effect of the herbal extract mixture on the proliferation of osteoblasts Was used to measure the amount of ³ H-thymidine that flowed into the DNA of the cells during cell growth. Specifically, osteoblasts were divided into 24-well plates at 2 × 10 ⁴ cells per well and replaced with DMEM containing 1% FBS the next day. In the culture broth which was replaced, the crude drug material extract mixture of the above example was diluted at a concentration of 1 × 10 ⁻⁴ to 1 mg / ml, added according to the concentration, and cultured for 48 hours.

Finally, 3 μCi / well of ³ H-thymidine was added for 4 hours and cultured, then the cells were washed with PBS (phosphate buffered saline) buffer, treated with 4% 5% TCA (trichloroacetic acid), and TCA. -The fraction that was insoluble was separated and dissolved with 0.1 M NaOH. Among these, a certain fraction was used to measure ³ H-thymidine influx by measuring radioactivity with a liquid scintillation counter.
The results are shown in Table 1 and FIG.

  As apparent from Table 1 and FIG. 1, the cells to which the herbal extract extract according to the present invention was added were about 120 to 130% as compared to the cells to which the eringi extract and the five peel extract were added alone. The above cell proliferation effect was shown.

2. Measurement of activity of basic phosphate degrading enzyme (alkaline phosphatase) which is a marker enzyme of osteoblasts In order to evaluate the influence of the herbal extract extract according to the present invention on the activity of osteoblasts, the cells were cultured in 1 above. HOS osteoblasts were divided into 96-well plates at 5 × 10 ³ cells per well and grown in a monolayer, and then the crude drug material extract was mixed with 0.08, 0.4, 1.0 , 5.0 and 10.0 mg / ml in culture and cultured in DMEM containing 10% FBS for 48 hours in a 96-well plate, after which the cells were treated with 0.1% Triton X-100 / Treated with saline at 37 ° C. for 30 minutes.

Then, a certain amount of the cell treatment solution was reacted with 0.1N glycine-NaOH buffer solution (pH 10.4) for 30 minutes at 37 ° C. in the presence of 100 mM PNPP (p-nitrophenylphosphate) as a substrate. The amount of PNP (p-nitrophenyl) released from a certain PNPP was colorimetrically determined at 405 nm.
The results are shown in Table 2 and FIG.

As is apparent from Table 2 and FIG. 2, the cells to which the herbal extract extract according to the present invention was added were more basic phosphate-degraded than the cells to which the eringi extract and the five skin extract were added alone. The enzyme activity increased by about 110 to 150%.
Therefore, it can be seen that the herbal extract extract according to the present invention exhibits an excellent activity for basic phosphatase, which is an osteoblast labeling enzyme, and is therefore effective for the proliferation of osteoblasts.

<< Experimental Example 2: Osteoclast Proliferation Inhibitory Action by Herbal Extract Extract of the Present Invention >>
In order to examine how the herbal extract mixture according to the present invention affects the growth and activity of osteoclasts, osteoclast progenitor cells were placed on a calcium-phosphate coated plate (OAAS, OCT Inc.). After culturing, the activity of TRAP (Tartrate-resistant acid phosphatase; hereinafter abbreviated as TRAP), which is an osteoclast labeling enzyme, was analyzed.

1. Pure isolation of osteoclast progenitors and induction of differentiation into mature osteoclasts In order to isolate mouse bone marrow cells, male mice at 7-9 weeks were sacrificed by cervical torsion, followed by femur and tibia Was aseptically removed, soft tissue was removed, and both ends of the iliac were cut. Next, the bone marrow was removed by injecting 1 ml of an enzyme solution containing 0.1% collagenase (Gibco), 0.05% trypsin and 0.5 mM EDTA (Gibco) into one bone marrow cavity using a 26G needle. It was. Thereafter, the mixture was stirred for 30 minutes, and bone marrow cells were collected and pre-cultured in α-MEM (α-minimum essential medium) containing 10% FBS for 24 hours to collect unattached cells.

Then, unattached cells that become osteoclast progenitor cells were separated and cultured so as to be 2 × 10 ⁵ cells per well. During culturing for 8 days (however, the culture medium was replaced on the 3rd and 6th days and replaced with the culture medium supplemented with the extract), 20 ng / ml macrophage-colony stimulating factor; M-CSF, Peprotech, USA) and α-MEM containing 30 ng / ml RANKL (Peprotech, USA) were treated with the herbal extract mixture of the above example and cultured (in all examples, 3 On the day and day 6, the extract was treated at the same time in the process of changing the culture solution to the concentrations shown in the table. After culturing, cells were fixed and TRAP staining was performed to examine osteoclast production.

2. Measurement of formation of multinucleated cells that are TRAP (+) The formation of osteoclasts is determined by culturing osteoclast progenitor cells on calcium-phosphate coated plates and then the number of multinucleated cells that show TRAP (+). Was observed. Specifically, after cell culture, adherent cells were washed with PBS, fixed with sheetate-acetate-formaldehyde for 5 minutes, naphthol AS-BI phosphate (phosphate), fast TRAP staining was performed by culturing in 37 ° C. acetate buffer (pH 5.0) containing a fast Garnet GBC solution and 7 mM tartrate buffer (pH 5) for 1 hour. TRAP (+) multinucleated cells with more than two nuclei were considered osteoclasts.
The results are shown in Table 3 and FIG.

  As apparent from Table 3 and FIG. 3, when the eringi extract was treated alone, the growth inhibition rate of the control (concentration 0) was 0, and the growth inhibition rate of the number of TRAP-positive multinuclear cells relative to the control was 0. Osteoclast formation was suppressed at concentrations of 5, 1.0 and 2.5 mg / ml at 16.57, 31.54 and 87.03%. In addition, when the five peel extract was treated alone, it was 14.77, 61.08, 92.22, 99.20 at concentrations of 0.5, 1.0, 2.5, and 5.0 mg / ml, respectively. % And osteoclast formation was inhibited.

In addition, when the concentrations of the eringi extract and the quince extract are mixed at 0.5 mg / ml or more, the growth inhibition rate as the herbal extract extract is the growth inhibition rate of the eringi extract and the quince extract. It was shown as the rest of the product excluding the growth inhibition rate. From Table 1, the generation of osteoclasts was significantly suppressed as compared with the case where each was treated alone.
From the above experimental results, it can be seen that the herbal extract extract according to the present invention remarkably suppresses the formation of osteoclasts as compared with the case where the eringi extract and the pentagonal extract were each treated alone. .

«Experimental Example 3: Acute toxicity study of oral administration to rats»
In order to investigate the acute toxicity of the crude drug material extract mixture of the present invention, an acute toxicity experiment was conducted by the following method. That is, acute toxicity experiments were conducted using 6-week-old specific pathogen-free (SPF) SD rats as experimental animals. The herbal extract of the present invention was suspended in 0.5% methylcellulose solution and administered orally once to a group of 2 animals per group in a volume of 1 g / kg / ml. After administration of the test substance, observe whether the animal is dead or dead, clinical symptoms, change in body weight, perform hematological and biochemical tests, and perform autopsy to visually check for abnormalities in the abdominal and thoracic organs did.

As a result, there were no notable clinical symptoms in any animals to which the test substance was administered, no dead animals, and no toxic changes were observed in body weight changes, blood tests, blood biochemical tests, autopsy findings, and the like. Therefore, none of the crude drug material extract mixtures according to the present invention show toxicity changes in rats up to 1 g / kg, and the minimum lethal dose (LD ₅₀ ) for oral administration is a safe substance of 1 g / kg or more of the extract. It was determined that

Here, the formulation example for the crude drug material extract mixture which concerns on this invention below is illustrated.
<< Formulation Example 1: Production of pharmaceutical preparation >>
1. Manufacture of powder herbal medicine extract mixture 2g
1g of lactose
The above ingredients were mixed and filled into an airtight bag to produce a powder.

2. Manufacture of tablets Herbal extract extracts 100mg
Corn starch 100mg
Lactose 100mg
Magnesium stearate 2mg
After mixing the above-mentioned components, the tablet was produced by a conventional tablet production method to produce a tablet.

3. Manufacture of capsule herbal extract 100mg
Corn starch 100mg
Lactose 100mg
Magnesium stearate 2mg
After the above components were mixed, the capsules were manufactured by filling gelatin capsules by an ordinary capsule manufacturing method.

<< Formulation Example 2: Production of Food >>
The foodstuff containing the crude drug material extract mixture of this invention was manufactured as follows.
1. Preparation of a seasoning for cooking A seasoning for cooking health was prepared using an amount of the herbal extract of the present invention in an amount of 20 to 95% by weight.

2. Manufacture of tomato ketchup and sauce Tomato ketchup or sauce for health promotion was prepared by adding the herbal extract extract of the present invention to the tomato ketchup or sauce so as to be 0.2 to 1.0% by weight.

3. Manufacture of flour foods Add 0.5% to 5.0% by weight of the herbal extract mixture of the present invention to wheat flour, and use this mixture to produce bread, cakes, cookies, crackers and noodles to improve health Manufactured.

4). Manufacture of soups and gravies 0.1 to 5.0% by weight of the herbal extract mixture of the present invention was added to the soups and gravy to produce health processed meat processed products, noodle soup and gravy.

5). Production of ground beef 10% by weight of the herbal extract of the present invention was added to the ground beef to produce a ground beef for health promotion.

6). Manufacture of dairy products 5-10% by weight of the herbal extract mixture of the present invention was added to milk, and various dairy products such as butter and ice cream were manufactured using the milk.

7). Manufacture of Zen Food After roasting brown rice, barley, brown rice and pigeons that had been pregelatinized and dried by a known method, it was manufactured into a powder with a particle size of 60 mesh using a grinder.
After steaming and drying black beans, black sesame, and sesame sesame seeds by a known method, they were produced into a powder with a particle size of 60 mesh using a pulverizer.
The dried product obtained by decompressing and concentrating the mixture of herbal extracts of the present invention with a vacuum concentrator, spraying and drying with a hot air dryer was pulverized to a particle size of 60 mesh using a pulverizer to obtain a dry powder. .
The dry powders of the cereals, seeds and herbal extracts extracted as described above were blended in the following proportions.

Cereals (brown rice 30% by weight, pigeon 15% by weight, barley 20% by weight),
Seeds (salmon sesame 7% by weight, black beans 8% by weight, black sesame 7% by weight),
Herbal extract extract dry powder (3% by weight),
Ganoderma (0.5 wt%),
Ground yellow (0.5 wt%)

<< Formulation Example 3: Production of Beverage >>
1. Manufacture of carbonated drinks Additives of sugar 5-10%, citric acid 0.05-0.3%, caramel 0.005-0.02%, vitamin C 0.1-1%, 94% purified water is mixed to make a syrup. The syrup is sterilized at 85 to 98 ° C. for 20 to 180 seconds and mixed with cooling water at a ratio of 1: 4. A carbonated beverage containing the herbal extract extract of the present invention was manufactured by injecting .82%.

2. Manufacture of health drinks Instantly blend liquid ingredients such as liquid fructose 0.5%, oligosaccharide 2%, sugar 2%, salt 0.5%, water 75%, and herbal extract mixture. After sterilization, this was packaged in small packaging containers such as glass bottles and PET bottles to produce health drinks.

3. Production of vegetable juice 5 g of the herbal extract extract of the present invention was added to 1,000 ml of tomato or carrot juice to produce vegetable juice for health promotion.

4). Manufacture of fruit juice 1 g of the herbal extract extract of the present invention was added to 1,000 ml of apple or grape juice to produce fruit juice for health promotion.

  The herbal extract mixture according to the present invention is widely used as a pharmaceutical and a health food useful for the prevention and treatment of osteoporosis in order to proliferate osteoblasts and effectively suppress osteoclast formation and activity. It is possible.

It is a figure which shows the influence which the herbal medicine extract mixture of this invention has on the proliferation of an osteoblast. It is a figure which shows the influence which the crude drug material extract mixture of this invention has on the activity of the basic phosphatase of osteoblast. It is a figure which shows the growth-inhibition rate of the osteoclast by the herbal material extract mixture of this invention.

Claims (1)

  It contains 0.5 to 2.5 parts by weight of the eringi extract as a solid content and 0.5 to 5.5 parts by weight of the quince extract as a solid content. A pharmaceutical composition for treating or preventing osteoporosis, comprising 0 part by weight.

Images